On 30 de out. de 2025, ARGX reported earnings of 5.18 USD per share (EPS) for Q3 25, beating the estimate of 4.36 USD, resulting in a 18.63% surprise. Revenue reached 1.15 bilhão, compared to an expected 1.08 bilhão, with a 6.87% difference. The market reacted with a -0.20% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 18 analistas forecast an EPS of 6.41 USD, with revenue projected to reach 1.31 bilhão USD, implying an aumentar of 23.75% EPS, and aumentar of 13.41% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
22 de dez. de 2025 Para Q4 25
Estimativa
-$0.57
Real
-$0.73
Surpresa
-25.95%
Outlook Therapeutics, Inc. Common Stock
Report Date
19 de dez. de 2025 Para Q4 25
Estimativa
-$0.25
Real
-$0.19
Surpresa
+26.47%
Citius Oncology, Inc. Common Stock
Report Date
23 de dez. de 2025 Para Q4 25
Estimativa
-$0.12
Real
-$0.06
Surpresa
+50.98%
FAQ
What were argenx SE - ADR's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, argenx SE - ADR reported EPS of $5.18, beating estimates by 18.63%, and revenue of $1.15B, 6.87% above expectations.
How did the market react to argenx SE - ADR's Q3 2025 earnings?
The stock price moved down -0.2%, changed from $821.97 before the earnings release to $820.36 the day after.
When is argenx SE - ADR expected to report next?
The next earning report is scheduled for 26 de fev. de 2026.
What are the forecasts for argenx SE - ADR's next earnings report?
Based on 18
analistas, argenx SE - ADR is expected to report EPS of $6.41 and revenue of $1.31B for Q4 2025.